The University of California, Berkeley, and collaborators are contesting the US Patent and Trademark Offices Patent Trial and Appeal Board (PTAB)’s February decision that their own patent application on CRISPR gene-editing technology does not overlap with a patent owned by the Broad Institute of MIT and Harvard .
Week in Review: April 10–14
CRISPR patent ruling appealed; CRISPR-based nucleic acid test; an experimental gene therapy for Duchenne muscular dystrophy and a cell-based protocol for Parkinson’s disease show promise in mice
Written byTracy Vence
| 3 min read
Register for free to listen to this article
Listen with Speechify
0:00
3:00
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred Google source to see more of our trusted coverage.
Meet the Author
Tracy Vence was an editor at The Scientist from 2013 to 2017.
View Full Profile
Related Topics
